TRAMOGET-P Tablets

TRAMOGET-P Tablets
Tramadol 37.5 mg + Paracetamol 325 mg

Tramadol is a centrally acting synthetic analgesic compound whose analgesic prbfile can be attributed to the
binding of parent and 0-demethylated (M1) metabolite to p.-opioid receptors as well as the weak inhibition of
neuronal re-uptake of noradrenaline and serotonin.

Paracetamol also has centrally acting analgesic effects.

Tramadol is well absorbed after oral administration, reaching peak activity in 2 to 3 hours. The mean absolute
bioavailability of a single 100 mg oral dose is approximately 75%, increasing to approximately 90% with
multiple dosing. Oral absorption of paracetamol following administration of Tramace-P gives a peak plasma
concentration of paracetamol within one hour and is not affected by co-administration with tramadol.
Tramadol and paracetamol are both extensively metabolised in the liver. Approximately 30% of tramadol is
excreted unchanged in the urine. Tramadol and its metabolites are eliminated primarily by the kidney. The
plasma elimination half-lives of tramadol and its M1 metabolite are approximately 6 and 7 hours respectively.
Paracetamol is eliminated from the body primarily by formation of glucuronide and sulfate conjugates in a
dose-dependent manner. The half-life of paracetamol is about 2-3 hours in adults. Less than 9% of
paracetamol is excreted unchanged in the urine.

INDICATIONS

Tramoget is indicated for the short-term treatment (i.e. three days or less) of mild to moderate ac a.e pain.

DOSAGE AND DIRECTIONS FOR USE

To be used in adults and children over 16 years of age. Do not exceed the recommended dose.

Acute pain:

1 tablets every 6 hours or as needed for pain relief. Do not exceed 4 tablets per cm

Renal impairment:

For patients with creatinine clearance <30 mL/min, the dosing interval of Tramoget should be increased not to exceed 2 tablets every 12 hours.